MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges

Alireza Mansouri, Laureen D. Hachem, Sheila Mansouri, Farshad Nassiri, Normand J. Laperriere, Daniel Xia, Neal I. Lindeman, Patrick Y. Wen, Arnab Chakravarti, Minesh P. Mehta, Monika E. Hegi, Roger Stupp, Kenneth D. Aldape, Gelareh Zadeh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O 6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice.

Original languageEnglish (US)
Pages (from-to)167-178
Number of pages12
JournalNeuro-oncology
Volume21
Issue number2
DOIs
StatePublished - Feb 14 2019

Fingerprint

Glioblastoma
Transferases
Methylation
DNA
Biomarkers
Epigenomics
Brain Neoplasms
Consensus
Decision Making
Therapeutics
Survival
Research
Genes
O-(6)-methylguanine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Mansouri, Alireza ; Hachem, Laureen D. ; Mansouri, Sheila ; Nassiri, Farshad ; Laperriere, Normand J. ; Xia, Daniel ; Lindeman, Neal I. ; Wen, Patrick Y. ; Chakravarti, Arnab ; Mehta, Minesh P. ; Hegi, Monika E. ; Stupp, Roger ; Aldape, Kenneth D. ; Zadeh, Gelareh. / MGMT promoter methylation status testing to guide therapy for glioblastoma : Refining the approach based on emerging evidence and current challenges. In: Neuro-oncology. 2019 ; Vol. 21, No. 2. pp. 167-178.
@article{aa0225532dcc4efbb87d7b8447802190,
title = "MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges",
abstract = "Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O 6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice.",
author = "Alireza Mansouri and Hachem, {Laureen D.} and Sheila Mansouri and Farshad Nassiri and Laperriere, {Normand J.} and Daniel Xia and Lindeman, {Neal I.} and Wen, {Patrick Y.} and Arnab Chakravarti and Mehta, {Minesh P.} and Hegi, {Monika E.} and Roger Stupp and Aldape, {Kenneth D.} and Gelareh Zadeh",
year = "2019",
month = "2",
day = "14",
doi = "10.1093/neuonc/noy132",
language = "English (US)",
volume = "21",
pages = "167--178",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "2",

}

Mansouri, A, Hachem, LD, Mansouri, S, Nassiri, F, Laperriere, NJ, Xia, D, Lindeman, NI, Wen, PY, Chakravarti, A, Mehta, MP, Hegi, ME, Stupp, R, Aldape, KD & Zadeh, G 2019, 'MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges', Neuro-oncology, vol. 21, no. 2, pp. 167-178. https://doi.org/10.1093/neuonc/noy132

MGMT promoter methylation status testing to guide therapy for glioblastoma : Refining the approach based on emerging evidence and current challenges. / Mansouri, Alireza; Hachem, Laureen D.; Mansouri, Sheila; Nassiri, Farshad; Laperriere, Normand J.; Xia, Daniel; Lindeman, Neal I.; Wen, Patrick Y.; Chakravarti, Arnab; Mehta, Minesh P.; Hegi, Monika E.; Stupp, Roger; Aldape, Kenneth D.; Zadeh, Gelareh.

In: Neuro-oncology, Vol. 21, No. 2, 14.02.2019, p. 167-178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MGMT promoter methylation status testing to guide therapy for glioblastoma

T2 - Refining the approach based on emerging evidence and current challenges

AU - Mansouri, Alireza

AU - Hachem, Laureen D.

AU - Mansouri, Sheila

AU - Nassiri, Farshad

AU - Laperriere, Normand J.

AU - Xia, Daniel

AU - Lindeman, Neal I.

AU - Wen, Patrick Y.

AU - Chakravarti, Arnab

AU - Mehta, Minesh P.

AU - Hegi, Monika E.

AU - Stupp, Roger

AU - Aldape, Kenneth D.

AU - Zadeh, Gelareh

PY - 2019/2/14

Y1 - 2019/2/14

N2 - Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O 6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice.

AB - Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O 6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85061062763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061062763&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy132

DO - 10.1093/neuonc/noy132

M3 - Article

C2 - 30189035

AN - SCOPUS:85061062763

VL - 21

SP - 167

EP - 178

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 2

ER -